论文部分内容阅读
据外电报道美国北卡罗莱纳州消息:美国食品和药物管理局(FDA)已经批准使用一种治疗疱疹感染的新静脉注射剂。查佩尔希尔北卡罗莱纳大学肿瘤研究中心主任Joseph Pagano推测此药可被治疗接触过疱疹的肿瘤、骨髓或器官移植病人的医生“立即接收”. 估计每年有200,000例上述病人发生疱疹,其中约有5％死于此种病毒性感染. 去年春季,FDA批准Burroughs Wellco-me公司生产的一种抗病毒油膏:Zovirax.而这新药是Zovirax的一种静脉注射剂.
According to foreign reports North Carolina, USA: The U.S. Food and Drug Administration (FDA) has approved the use of a new intravenous injection for the treatment of herpes infections. Joseph Pagano, director of the Center for Oncology at the University of North Carolina at Chapel Hill, speculates that the drug is “immediately available” to physicians who treat patients with tumors, bone marrow or organ transplants who have been exposed to herpes. It is estimated that 200,000 cases of herpes, About 5% of these died of the viral infection, and last spring the FDA approved Zovirax, an anti-viral ointment from Burroughs Wellco-me, a parenteral vitamin Zovirax.